Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial

Amit M. Oza, Alla Lisyanskaya, Alexander N. Fedenko, Andréia Cristina de Melo, Yaroslav Shparyk, Irina Rakhmatullina, Igor Bondarenko, Nicoletta Colombo, Valentyn Svintsitskiy, Luciano Biela, Marina Nechaeva, Domenica Lorusso, Giovanni Scambia, David Cibula, Ròbert Póka, Ana Oaknin, Tamar Safra, Beata Maćkowiak-Matejczyk, Ling Ma, Daleen Thomas, Kevin Lin, Karen R. McLachlan, Sandra Goble, Rebecca Kristeleit